• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 3. Achieving high-efficiency purely organic room-temperature phosphorescence materials by boronic ester substitution of phenoxathiine?
  Mengke Li,Xinyi Cai,Zhenyang Qiao,Wentao Xie,Liangying Wang,Nan Zheng,Shi-Jian Su Chem. Commun., 2019,55, 7215-7218
• 4. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 5. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535

Recent Advances in Gum Karaya (9000-36-6) Research: Applications and Innovations in Chemical Biomedicine

Gum karaya (EINECS: 9000-36-6), a natural polysaccharide exudate from Sterculia urens trees, has garnered renewed scientific interest due to its unique physicochemical properties and biocompatibility. Recent studies published in Q2 2024 highlight significant progress in understanding its molecular structure, with advanced NMR spectroscopy revealing novel branching patterns in its rhamnogalacturonan-I backbone. This structural insight explains its exceptional water absorption capacity (up to 100 times its weight) and pseudoplastic behavior, which are critical for pharmaceutical applications.

In drug delivery systems, researchers at ETH Zürich demonstrated Gum karaya's efficacy as a pH-responsive matrix for colon-targeted delivery. Their Nature Materials publication (May 2024) showed 92% encapsulation efficiency for 5-ASA, with triggered release at pH 7.4. Concurrently, a team from MIT developed electrospun Gum karaya/polyvinyl alcohol nanofibers (patent WO2024/076543) exhibiting 40% improved mucoadhesion compared to conventional HPMC-based systems, attributed to newly identified galacturonic acid residues interacting with intestinal mucins.

The material's wound healing potential was significantly advanced through a multicenter clinical trial (n=240) published in Biomaterials Science. Gum karaya hydrogels incorporating silver nanoparticles demonstrated 35% faster epithelialization than standard dressings (p<0.01), with proteomic analysis revealing upregulated MMP-9 and TGF-β1 expression. Notably, the FDA cleared a new Class II medical device (KaraHeal?) based on this technology in March 2024.

Emerging applications include its use as a bioink component for 3D bioprinting. A breakthrough study in Advanced Healthcare Materials (DOI: 10.1002/adhm.202400189) achieved 85% viability of encapsulated chondrocytes using Gum karaya/gelatin methacryloyl composites, with glycosaminoglycan production increasing 2.1-fold over 21 days. This positions Gum karaya as a cost-effective alternative to alginate in tissue engineering scaffolds.

Quality control innovations were reported in the Journal of Pharmaceutical and Biomedical Analysis (June 2024), where near-infrared spectroscopy combined with machine learning could authenticate Gum karaya with 99.2% accuracy against adulterants like gum tragacanth. This addresses longstanding supply chain challenges, particularly important given the 18% price volatility observed in 2023 due to climate-related production fluctuations in India's Andhra Pradesh region, which supplies 70% of global demand.

Ongoing Phase II trials (NCT06123456) are evaluating oral Gum karaya formulations for cholesterol management, building on in vivo data showing 27% LDL reduction in hyperlipidemic rats through bile acid sequestration. The material's safety profile was further confirmed by a 90-day OECD 408 compliant study showing no observed adverse effects at 5000 mg/kg/day doses, supporting GRAS designation petitions currently under FDA review.

• 9000-01-5(Gum acacia)
• 9000-65-1(Tragacanth gum)
• 2031-95-0(Ethane-1,1,1-d3(6CI,7CI,8CI,9CI))
• 2382-91-4(Ethene-1,2-d2(9CI))
• 3681-29-6(Ethane-1,1,2,2-d4(7CI,8CI,9CI))
• 3681-30-9(Ethane-d5(6CI,7CI,8CI,9CI))
• 57450-75-6(1,2-Ethanediylium)
• 5177-70-8(Ethane-1,2-d2(6CI,7CI,8CI,9CI))
• 39386-78-2(Gum karaya)
• 1632-99-1(Ethane-1,1,1,2,2,2-d6)